Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (47)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pincus, T.
Right arrow Articles by Wolfe, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pincus, T.
Right arrow Articles by Wolfe, F.
Related Collections
Right arrow Diagnostics and Imaging Procedures
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 1346-1356
© 2002 British Society for Rheumatology

Review

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review

T. Pincus1,, G. Ferraccioli2, T. Sokka1,,3, A. Larsen4, R. Rau5, I. Kushner6 and F. Wolfe7

1 Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University School of Medicine, 203 Oxford House, Nashville, TN 37232-4500, USA,
2 Division of Rheumatology, Department of Internal Medicine, DPMSC, School of Medicine of Udine, 33100 Udine, Italy,
3 Jyvaskyla Central Hospital, 40620 Jyvaskyla, Finland,
4 Rheumatology Department, Kongsvinger Sjukehus, N-2226 Kongsvinger, Norway,
5 Evangelisches Fachkrankenhaus, Rheumaklinik, Rosenstrasse 2, D-40882 Ratingen, Germany,
6 Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center Campus, 2500 MetroHealth Drive, Cleveland, OH 44109-1998 and
7 Wichita Arthritis Center, 1035 North Emporia, #230, Wichita, KS 67214, USA

Earlier reports, including a comprehensive 1983 review, had indicated that slowing of radiographic progression was relatively unusual in treatment of rheumatoid arthritis (RA) using traditional disease modifying anti-rheumatic drugs. However, in recent years, slowing of radiographic progression has been documented in a number of clinical trials, as well as long-term observational studies, with use of (in alphabetical order) adalimumab, anakinra, corticosteroids, cyclophosphamide, cyclosporin, etanercept, gold salts, infliximab, leflunomide, methotrexate and sulphasalazine. At this time, disease modification is a realistic goal in the clinical care of patients with RA. Documentation of improved long-term outcomes requires long-term observational data over 5–20 yr to supplement data from randomized controlled clinical trials over 6–24 months.

Correspondence to: T. Pincus, Vanderbilt University School of Medicine, Division of Rheumatology and Immunology, 203 Oxford House, Nashville, TN 37232, USA.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
J. A. M. Wessels, T. W. J. Huizinga, and H.-J. Guchelaar
Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis
Rheumatology, March 1, 2008; 47(3): 249 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Stat Methods Med ResHome page
G. S. Park, Weng Kee Wong, M. Oh, D. Khanna, R. H. Gold, J. T. Sharp, and H. E. Paulus
Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences
Statistical Methods in Medical Research, February 1, 2007; 16(1): 13 - 29.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. Pincus and T. Sokka
How aggressive should initial therapy for rheumatoid arthritis be?
Rheumatology, January 1, 2005; 44(1): 133 - 134.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. Kaarela, M. Hakala, P. Hannonen, H. Kautiainen, M. Korpela, M. Leirisalo-Repo, R. Luosujarvi, R. Luukkainen, T. Mottonen, and K. Puolakka
How aggressive should initial therapy for rheumatoid arthritis be? The Finnish experience
Rheumatology, January 1, 2005; 44(1): 134 - 135.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. Larsson, H. Erlandsson Harris, A. Larsson, B. Mansson, T. Saxne, and L. Klareskog
Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP
Rheumatology, April 1, 2004; 43(4): 428 - 434.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.